person · Reporting owner

NODELMAN OLEG

Disclosed activity across 6 companies

Tapewire entity: 69542
SEC CIK: 0001454385

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ANAPTYSBIO, INCANAB · Entity 4640	Director · 10% owner	December 30, 2024	January 02, 2025
Aktis Oncology, Inc.AKTS · Entity 4711	Director	January 12, 2026	January 13, 2026
Nuvation Bio Inc.NUVB · Entity 4384	Director	September 19, 2023	September 22, 2023
PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375	Director · 10% owner	December 03, 2019	December 13, 2019
Zymeworks Inc.ZYME · Entity 4458	Director · 10% owner	June 26, 2025	June 27, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANAPTYSBIO, INC

Report date December 30, 2024 · Filed January 02, 2025

Jointly reported with EcoR1 Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Note	7,860,180	Reported balance After 2024-12-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-12-30 · Purchase · Acquired 65,184 · Balance 7,860,180 F2: Qualified Fund purchased all of the securities in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3. F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Note	7,873,448	Reported balance After 2024-12-31 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-12-31 · Purchase · Acquired 13,268 · Balance 7,873,448 F5: Qualified Fund purchased all of the securities in this transaction. F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Note	7,880,094	Reported balance After 2025-01-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-01-02 · Purchase · Acquired 6,646 · Balance 7,880,094 F7: Qualified Fund purchased all of the securities in this transaction. F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.

F2: Qualified Fund purchased all of the securities in this transaction.

F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3.

F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock.

F5: Qualified Fund purchased all of the securities in this transaction.

F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock.

F7: Qualified Fund purchased all of the securities in this transaction.

F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 13, 2026

Jointly reported with EcoR1 Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Note	2,270,879	Reported balance After 2026-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 2,270,879 · Balance 2,270,879 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Common StockSEC Table I · non-derivative	IndirectSee Note	202,862	Reported balance After 2026-01-12 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-01-12 · Conversion · Acquired 202,862 · Balance 202,862 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Common StockSEC Table I · non-derivative	IndirectSee Note	128,506	Reported balance After 2026-01-12 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 128,506 · Balance 128,506 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Common StockSEC Table I · non-derivative	IndirectSee Note	4,348,658	Reported balance After 2026-01-12 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 2,077,779 · Balance 4,348,658 F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Common StockSEC Table I · non-derivative	IndirectSee Note	347,305	Reported balance After 2026-01-12 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2026-01-12 · Purchase · Acquired 144,443 · Balance 347,305 F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee note	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 9,913,810 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee note	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 997,299 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee note	0	Reported balance After 2026-01-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-12 · Conversion · Disposed 488,891 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee note	0	Reported balance After 2026-01-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-12 · Conversion · Disposed 2,397,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee note	0	Reported balance After 2026-01-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-12 · Conversion · Disposed 102,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Class A Common StockSEC Table II · derivative / convertible security	IndirectSee note	965,190	Reported balance After 2026-01-12 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-01-12 · Conversion · Acquired 965,190 · Balance 965,190 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
Class A Common StockSEC Table II · derivative / convertible security	IndirectSee Note	86,222	Reported balance After 2026-01-12 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-01-12 · Conversion · Acquired 86,222 · Balance 86,222 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.

F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.

F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.

F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.

F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date.

Nuvation Bio Inc.

Report date September 19, 2023 · Filed September 22, 2023 · Amendment

Jointly reported with EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee Notes	12,674,775	Last balance in matching sequence After 2023-09-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2023-09-19 · Purchase · Acquired 5,143,000 · Balance 12,504,675 F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 2 · 2023-09-20 · Purchase · Acquired 117,100 · Balance 12,621,775 F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 3 · 2023-09-21 · Purchase · Acquired 53,000 · Balance 12,674,775 F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities.

Filing footnotes · ownership attribution and instrument terms

F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2: Qualified Fund is the record holder of these securities.

F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.

F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.

F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.

PROTHENA CORP PUBLIC LTD CO

Report date December 03, 2019 · Filed December 13, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectSee Note	9,426,640	Reported balance Holding disclosure · report date 2019-12-03 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 9,426,640 F1: Mr. Nodelman is the manager and controlling owner of EcoR1 Capital, LLC ("EcoR1"), an investment adviser to private investment funds (the "Funds"). The Funds hold these securities directly for the benefit of their investors, EcoR1 indirectly beneficially owns such securities as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. Mr. Nodelman disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein and disclaims membership in a group with the Funds within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Nodelman is the manager and controlling owner of EcoR1 Capital, LLC ("EcoR1"), an investment adviser to private investment funds (the "Funds"). The Funds hold these securities directly for the benefit of their investors, EcoR1 indirectly beneficially owns such securities as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. Mr. Nodelman disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein and disclaims membership in a group with the Funds within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.

Zymeworks Inc.

Report date June 26, 2025 · Filed June 27, 2025

Jointly reported with EcoR1 Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Note	22,970,388	Reported balance After 2025-06-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-06-26 · Other · Acquired 5,086,480 · Balance 22,970,388 F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Note	22,970,388	Reported balance After 2025-06-26 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-06-26 · Tax withholding · Disposed 41 · Balance 22,970,388 F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
Pre-Funded Warrants (right to acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee note	0	Reported balance After 2025-06-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-26 · Other · Disposed 5,086,521 · Balance 0 F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction. F6: The pre-funded warrants did not have an expiration date. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants.

F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock.

F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares.

F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction.

F6: The pre-funded warrants did not have an expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Panacea Acquisition Corp. II

Report date April 28, 2023 · Filed May 02, 2023

Jointly reported with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC

Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A ordinary sharesSEC Table I · non-derivative	Direct	0	Reported balance After 2023-04-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.

F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 31, 2021 Filed Nov 30, 2021 18:07 UTC	Nuvation Bio Inc. NUVB · Entity 4384	SaleClass A Common Stock	56,598	$8.64	$489,006.72	Disclosure SEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,147,483 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document
July 31, 2021 Filed Nov 30, 2021 18:07 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	56,598	$8.64	$489,006.72	Disclosure SEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 7,198,407 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document
May 04, 2021 Filed May 4, 2021 16:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	PurchaseCommon Stock	165,000	$23.25	$3,835,755.00	Disclosure SEC source: 0001567619-21-008992 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,520,424 F4 · shares: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,374,066 shares of the Issuer's Common Stock. F4 · balance_after: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,374,066 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
May 03, 2021 Filed May 4, 2021 16:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	PurchaseCommon Stock	20,800	$23.31	$484,872.96	Disclosure SEC source: 0001567619-21-008992 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,355,424 F3 · shares: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,209,066 shares of the Issuer's Common Stock. F3 · balance_after: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,209,066 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
April 30, 2021 Filed May 4, 2021 16:51 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	PurchaseCommon Stock	35,700	$23.16	$826,815.57	Disclosure SEC source: 0001567619-21-008992 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,334,624 F2 · shares: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,188,266 shares of the Issuer's Common Stock. F2 · balance_after: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,188,266 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
April 27, 2021 Filed Apr 27, 2021 18:23 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	PurchaseCommon Stock	33,800	$23.82	$805,088.96	Disclosure SEC source: 0001567619-21-008650 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,298,924 F2 · shares: Qualified Fund purchased all of the securities described in this transaction. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
April 26, 2021 Filed Apr 27, 2021 18:23 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	PurchaseCommon Stock	13,900	$23.80	$330,858.92	Disclosure SEC source: 0001567619-21-008650 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,265,124 F2 · shares: Qualified Fund purchased all of the securities described in this transaction. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
April 23, 2021 Filed Apr 27, 2021 18:23 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	PurchaseCommon Stock	99,600	$23.54	$2,344,285.20	Disclosure SEC source: 0001567619-21-008650 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,251,224 F2 · shares: Qualified Fund purchased all of the securities described in this transaction. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
April 13, 2021 Filed Apr 13, 2021 17:55 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	3,966	$10.27	$40,734.79	Disclosure SEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,355,625 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document
April 13, 2021 Filed Apr 13, 2021 17:55 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	27,534	$10.27	$282,801.71	Disclosure SEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,990,265 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document
April 12, 2021 Filed Apr 13, 2021 17:55 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	16,745	$9.49	$158,873.21	Disclosure SEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,351,659 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document
April 12, 2021 Filed Apr 13, 2021 17:55 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	116,255	$9.49	$1,103,004.19	Disclosure SEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,962,731 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document
April 09, 2021 Filed Apr 13, 2021 17:55 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	37,770	$10.03	$378,855.76	Disclosure SEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,334,914 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document
April 09, 2021 Filed Apr 13, 2021 17:55 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	262,230	$10.03	$2,630,324.24	Disclosure SEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,846,476 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document
April 09, 2021 Filed Apr 13, 2021 15:10 UTC	Panacea Acquisition Corp. II PANA · Entity 114006	PurchaseClass A ordinary shares	545,000	$10.00	$5,450,000.00	Disclosure SEC source: 0001213900-21-021365 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 F1 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document
March 31, 2021 Filed Nov 30, 2021 18:07 UTC	Nuvation Bio Inc. NUVB · Entity 4384	SaleClass A Common Stock	151,544	$10.45	$1,583,634.80	Disclosure SEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,145,600 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document
March 31, 2021 Filed Nov 30, 2021 18:07 UTC	Nuvation Bio Inc. NUVB · Entity 4384	PurchaseClass A Common Stock	151,544	$10.45	$1,583,634.80	Disclosure SEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 6,735,790 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantWarrant (Right to Buy) · Derivative	131,333	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 12 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 131,333 Underlying: Class A Common Stock · 131,333 shares Expires not disclosed F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantWarrant (Right to Buy) · Derivative	702,000	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 11 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 702,000 Underlying: Class A Common Stock · 702,000 shares Expires not disclosed F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantWarrant (Right to Buy) · Derivative	130,000	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 10 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 130,000 Underlying: Class A Common Stock · 130,000 shares Expires not disclosed F10 · price: Warrants included in units purchased in a private placement by EcoR1 Panacea Holdings, LLC for $10.00 per unit in connection with Panacea's initial public offering. Each unit consisted of one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. Upon the closing of the Business Combination, the warrants may be deemed to be derivative securities for purposes of Section 16. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	ConversionClass B Common Stock · Derivative	2,775,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 9 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 0 Underlying: Class A Common Stock · 2,775,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	2,200,627	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 8 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,200,627 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F8 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Venture Opportunity Fund, LP, which is the owner of record of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	515,879	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 7 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 1,297,144 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	2,365,511	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 6,584,246 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	387,265	$10.00	$3,872,650.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 781,265 F6 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	2,112,735	$10.00	$21,127,350.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 4,218,735 F6 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	394,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 394,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	2,106,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,106,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document
February 10, 2021 Filed Feb 12, 2021 20:59 UTC	Nuvation Bio Inc. NUVB · Entity 4384	ConversionClass A Common Stock	2,775,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 3,165,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document
July 06, 2020 Filed Jul 6, 2020 17:06 UTC	Nuvation Bio Inc. PANA · Entity 4384	PurchaseClass A common stock	390,000	$10.00	$3,900,000.00	Disclosure SEC source: 0001213900-20-016762 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings, LLC · CIK 0001816134 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 F1 · shares: The reported shares are included within the 390,000 private placement units of the issuer purchased by EcoR1 Panacea Holdings, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of Class A common stock of the issuer and one-third of one redeemable warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. F2 · ownership.direct: The reporting owner, the Sponsor, in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.